 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 2 | 1 | 3 | | 1994 | 1 | 1 | 2 | | 1996 | 2 | 1 | 3 | | 1997 | 2 | 5 | 7 | | 1998 | 0 | 2 | 2 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 5 | 6 | | 2001 | 2 | 4 | 6 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 4 | 5 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 3 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 4 | 6 | 10 | | 2008 | 3 | 7 | 10 | | 2009 | 4 | 8 | 12 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 7 | 9 | | 2012 | 6 | 10 | 16 | | 2013 | 6 | 10 | 16 | | 2014 | 10 | 9 | 19 | | 2015 | 8 | 7 | 15 | | 2016 | 6 | 1 | 7 | | 2017 | 8 | 6 | 14 | | 2018 | 6 | 2 | 8 | | 2019 | 7 | 7 | 14 | | 2020 | 3 | 2 | 5 | | 2021 | 7 | 5 | 12 | | 2022 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Ananthapadmanabhan V, Frost TC, Soroko KM, Knott A, Magliozzi BJ, Gokhale PC, Tirunagaru VG, Doebele RC, DeCaprio JA. Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. JCI Insight. 2022 07 08; 7(13).
-
Ghazipura M, Mammen MJ, Herman DD, Hon SM, Bissell BD, Macrea M, Kheir F, Khor YH, Knight SL, Raghu G, Wilson KC, Hossain T. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2022 06; 19(6):1040-1049.
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. J Cyst Fibros. 2022 Jul; 21(4):637-643.
-
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022 03 01; 205(5):529-539.
-
Wisniewski BL, Aylward SC, Jordan CO, Kopp BT, Paul GR. Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis. J Cyst Fibros. 2022 05; 21(3):e217-e220.
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021 10 06; 11(1):19810.
-
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825.
-
Chen AW, Biggar K, Nygard K, Singal S, Zhao T, Li C, Nathanielsz PW, Jansson T, Gupta MB. IGFBP-1 hyperphosphorylation in response to nutrient deprivation is mediated by activation of protein kinase Ca (PKCa). Mol Cell Endocrinol. 2021 10 01; 536:111400.
-
Basu S, Mak T, Ulferts R, Wu M, Deegan T, Fujisawa R, Tan KW, Lim CT, Basier C, Canal B, Curran JF, Drury LS, McClure AW, Roberts EL, Weissmann F, Zeisner TU, Beale R, Cowling VH, Howell M, Labib K, Diffley JFX. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Biochem J. 2021 07 16; 478(13):2481-2497.
-
Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|